Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

Rosa Anna Bruno; Antonio Gasbarrini

doi:10.1016/j.dld.2014.06.009

Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

Rosa Anna Bruno, Antonio Gasbarrini

Risultato della ricerca: Contributo in rivista › Articolo in rivista

18 Citazioni (Scopus)

Abstract

We assessed the cost-effectiveness of boceprevir-based triple therapy compared to peginterferon alpha and ribavirin dual therapy in untreated patients with genotype 1 chronic hepatitis C; patients were discriminated according to the combination of baseline plus on-treatment predictors of boceprevir-based triple therapy.

Lingua originale	English
pagine (da-a)	936-942
Numero di pagine	7
Rivista	Digestive and Liver Disease
Volume	46
DOI	https://doi.org/10.1016/j.dld.2014.06.009
Stato di pubblicazione	Pubblicato - 2014

Keywords

Boceprevir
Cost-effectiveness
Peg-interferon

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.dld.2014.06.009

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{1216becfe16340a98ca58a1190b1608e,

title = "Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C",

abstract = "We assessed the cost-effectiveness of boceprevir-based triple therapy compared to peginterferon alpha and ribavirin dual therapy in untreated patients with genotype 1 chronic hepatitis C; patients were discriminated according to the combination of baseline plus on-treatment predictors of boceprevir-based triple therapy.",

keywords = "Boceprevir, Cost-effectiveness, Peg-interferon, Boceprevir, Cost-effectiveness, Peg-interferon",

author = "Bruno, {Rosa Anna} and Antonio Gasbarrini",

year = "2014",

doi = "10.1016/j.dld.2014.06.009",

language = "English",

volume = "46",

pages = "936--942",

journal = "Digestive and Liver Disease",

issn = "1590-8658",

publisher = "-Roma: Editrice Gastroenterologica Italiana. -Ospedaletto Pisa: Pacini",

}

TY - JOUR

T1 - Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

AU - Bruno, Rosa Anna

AU - Gasbarrini, Antonio

PY - 2014

Y1 - 2014

N2 - We assessed the cost-effectiveness of boceprevir-based triple therapy compared to peginterferon alpha and ribavirin dual therapy in untreated patients with genotype 1 chronic hepatitis C; patients were discriminated according to the combination of baseline plus on-treatment predictors of boceprevir-based triple therapy.

AB - We assessed the cost-effectiveness of boceprevir-based triple therapy compared to peginterferon alpha and ribavirin dual therapy in untreated patients with genotype 1 chronic hepatitis C; patients were discriminated according to the combination of baseline plus on-treatment predictors of boceprevir-based triple therapy.

KW - Boceprevir

KW - Cost-effectiveness

KW - Peg-interferon

KW - Boceprevir

KW - Cost-effectiveness

KW - Peg-interferon

UR - http://hdl.handle.net/10807/60727

U2 - 10.1016/j.dld.2014.06.009

DO - 10.1016/j.dld.2014.06.009

M3 - Article

SN - 1590-8658

VL - 46

SP - 936

EP - 942

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

ER -

Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo